190 related articles for article (PubMed ID: 34916713)
1. S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Miyajima N; Ragab Eissa I; Abdelmoneim M; Naoe Y; Ichinose T; Matsumura S; Bustos-Villalobos I; Mukoyama N; Morimoto D; Shibata M; Takeuchi D; Tsunoda N; Kikumori T; Tanaka M; Kodera Y; Kasuya H
Nagoya J Med Sci; 2021 Nov; 83(4):683-696. PubMed ID: 34916713
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T
Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397
[TBL] [Abstract][Full Text] [Related]
3. Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Abdelmoneim M; Eissa IR; Aboalela MA; Naoe Y; Matsumura S; Sibal PA; Bustos-Villalobos I; Tanaka M; Kodera Y; Kasuya H
Sci Rep; 2022 Dec; 12(1):21570. PubMed ID: 36513720
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
5. Other fluorinated pyrimidines in the treatment of solid tumors.
Saad ED; Hoff PM
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):65-8. PubMed ID: 11219980
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Triple Negative Breast Cancer Successfully Treated with S-1].
Nakayama Y; Inoue S; Mimura K; Nakazawa T; Kimura A; Ohmori M; Matsuda K; Ichikawa D
Gan To Kagaku Ryoho; 2018 Sep; 45(9):1343-1346. PubMed ID: 30237378
[TBL] [Abstract][Full Text] [Related]
8. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
10. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Van TT; Hanibuchi M; Kakiuchi S; Sato S; Kuramoto T; Goto H; Mitsuhashi A; Nishioka Y; Akiyama S; Sone S
Cancer Chemother Pharmacol; 2011 Aug; 68(2):497-504. PubMed ID: 21079960
[TBL] [Abstract][Full Text] [Related]
12. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Tsuda A; Fujiyama J; Miki A; Hori S; Ohtani H; Sawada Y
Cancer Chemother Pharmacol; 2008 Aug; 62(3):427-32. PubMed ID: 18026730
[TBL] [Abstract][Full Text] [Related]
13. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Nishimura G; Yanoma S; Mizuno H; Satake K; Taguchi T; Ikeda Y; Tsukuda M
Cancer Lett; 2000 Oct; 159(1):1-7. PubMed ID: 10974399
[TBL] [Abstract][Full Text] [Related]
15. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Saek T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Aoyama H; Ota J; Noguchi S; Taguchi T
Breast Cancer; 2004; 11(2):194-202. PubMed ID: 15550867
[TBL] [Abstract][Full Text] [Related]
17. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
18. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
[TBL] [Abstract][Full Text] [Related]
20. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
